The SIGN/BTS asthma guideline was recently updated. This update will have an impact on how many healthcare professionals care for people with asthma across the UK. We were fortunate to have the two co-chairs, Dr James Paton and Dr John White, on the podcast to talk us through the key updates in the guideline and some of the messages that they feel are important to communicate with pharmacists.
- Could you explain the context to the SIGN/BTS guideline?
- What should we call an asthma exacerbation and why?
- How did the SIGN/BTS guideline come to fruition?
- Do you think the SIGN/BTS guideline is UK centric?
- If you were messaging to pharmacists what top-line changes in this guideline update would you like to communicate to this population?
- When should FeNO be used and how does it relate to personalising asthma medication?
- In your view what is the value of validated questionnaires like the asthma control test?
- What are your top tips in terms of how to manage the asthmatic population within general practice?
